Antibody (Suitable for clinical applications)
Sample Type: FFPE Patient Samples.
Tested Applications: IHC. Approved for In Vitro Diagnostic Procedures on FFPE tissues. For tissue collection recommendations, please see datasheet sent with product.
|Recommended Dilution (Conc)
||Citrate Buffer pH 6.0
||30 min at RoomTemperature
Prior to use, inspect vial for the presence of any precipitate or other unusual physical properties. These can indicate that the antibody has degraded and is no longer suitable for patient samples. Please run positive and negative controls simultaneously with all patient samples to account and control for errors in laboratory procedure. Use of methods or materials not recommended by enQuire Bio including change to dilution range and detection system should be routinely validated by the user.
Anti-beta-Amyloid Protein Antibody Clone: BAM-10
Host and Isotype: Mouse IgG1
Recommended Positive Control Sample: Brain, Amyloidosis
Cellular Localization of Antibody BAM-10 Staining: Cytoplasmic
Buffer and Stabilizer: PBS with 1% BSA and 0.05% NaN3
Lot specific. Plese contact tech support
Immunogen: A synthetic beta-amyloid peptide (1-40) conjugated to KLH.
Storage Conditions: This antibody should be stored refrigerated (2-8°C). This product should not be used past the expiration date printed on the vial.
beta-Amyloid Protein Information for Pathologists
Amyloid beta (A4) precursor protein (APP) is part of the type 1 transmembrane protein family. The APP gene is located on chromosome 21 and encodes for a cell surface receptor and transmembrane precursor protein. There are three homologs of APP: APP, APLP1 and APLP2 (Mol Neurodegener 2011;6:27). Cleavage of APP sequentially by beta secretase (rate limiting step) and gamma secretase produces beta amyloid (amyloid beta, A4, Abeta) peptides of 40 - 43 amino acids, as well as other peptides that have transcriptional, antimicrobial, or antifungal activities (Curr Opin Neurol 2000;13:377). The beta amyloid sequence is unique to APP and is not present in APLP1 or APLP2.
Notable Clinical Features:
Alzheimer disease: progressive memory loss and cognitive impairment, mood and personality changes, depression, anxiety Â in part due to the accumulation of beta amyloid deposits in the brain. Cerebral amyloid angiopathy: dementia, intracranial hemorrhage Â due to beta amyloid deposits in the vasculature. Diagnosis Beta amyloid can be detected using Congo red staining, immunohistochemical staining or PET imaging. Alzheimer disease: the presence of beta amyloid plaques and neurofibrillary tangles is essential for the diagnosis of Alzheimer disease (Alzheimer Dementia 2012;8:1) but is not pathognomonic for the disease Â beta amyloid plaques may be seen in normal aging and neurofibrillary tangles can be present in other neurodegenerative disorders.
Limitations and Warranty
This antibody is manufactured in accordance with clinical good manufacturing practices in an ISO13485:2016 certified production facility. It is intended for multiple uses including in vitro diagnostic use and research use only applications. Please see vial label for expiration date. We strive to always deliver antibodies with a shelf life of at least two years.